Navigation Links
Aether to Develop Revolutionary Bio-inks with Science Director Karen Dubbin
Date:6/8/2017

Today Aether announced the company will develop a brand new line of bio-inks, spearheaded by Aether’s latest hire, Science Director Karen Dubbin.

Aether believes the nascent, but rapidly growing, bio-ink market is ripe for disruption by Aether’s passionate commitment to advancing humankind by creating powerful technologies and selling them at incredibly affordable prices.

Aether’s founding philosophy with 3D bioprinters was to make something better than anything else out there, and sell it at an unbelievable value. Now Aether will take this same philosophy and apply it to the burgeoning bio-inks market.

Aether intends to develop higher quality bio-inks than any other company, yet sell them at the lowest price on the market.

The key to unlocking the true potential of the bio-ink market is to work with the scientist Aether considers to be the very best person for the job. Aether believes that in Karen Dubbin the company has found the single most talented and capable person to lead this effort.

Karen Dubbin has attended MIT and Stanford and will receive her PhD from Stanford at the end of this summer, after which she will join Aether full-time as the company’s Science Director. Until then, she will work with Aether as a consultant to build the foundation for Aether’s upcoming bio-ink research and bio-ink product launch.

Karen Dubbin will collaborate with Aether CEO Ryan Franks and Aether’s amazing team of talented engineers to launch an introductory line of bio-inks, which the company expects to be available late 2017.

Aether Science Director Karen Dubbin said, “I’m very excited to join the team at Aether. I believe Aether’s bioprinting technology can make a substantial positive impact on medical research, and I’m looking forward to contributing to this thrilling field.”

In her young career, Karen Dubbin has already pioneered bio-ink research at Stanford University as part of the Heilshorn Biomaterials Group, and laid the foundation for Stanford’s bio-ink research to flourish after her departure.

She completed her B.S. at MIT in Materials Science and Engineering, where her research alongside incredible scientists such as Ali Khademhosseini and Harvey Lodish has been published in Advanced Materials, and the Journal of Biological Chemistry.

Since then, she received her M.S. and will soon receive her Ph.D. in Materials Science and Engineering from Stanford working with Sarah Heilshorn. At Stanford, Karen was awarded the Bio-X Bowes Fellowship and has given multiple talks at the Tissue Engineering and Regenerative Medicine International Society World Congress, World Biomaterials Congress, and the Materials Research Society where she was able to present her research in both bioprinting and spinal cord regeneration to a range of elite scientists from across the globe. Additionally, work from Karen’s PhD has been published in peer-reviewed journals such as Advanced Healthcare Materials.

The Aether 1 bioprinter is the most advanced 3D bioprinter in the world. The combination of the world’s most advanced bioprinter, Aether’s relentless drive to advance mankind, and the one-of-a-kind biomaterials skill set of Karen Dubbin, puts Aether in a stronger position than any company on Earth to dominate the bio-ink market and give society the massive benefits of the bioprinting revolution.

About Aether:

Aether is a San Francisco technology start-up and the creator of Aether 1 Bioprinter, the world’s most advanced 3D bioprinter.

Aether 1 allows users to print with up to 24 materials including filaments, liquids, viscous pastes and gels. Aether 1 features up to 8 different fabrication methods, and comes with 4 completely revolutionary automation features utilizing technologies such as machine vision.

Despite being the world’s most advanced 3D bioprinter, Aether plans to sell base units of the beta edition for $9,000, a tiny fraction of their actual value.

Find out more:

http://www.aether1.com

http://bioprinting.aether1.com/

Read the full story at http://www.prweb.com/releases/2017/06/prweb14407256.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. Queensland University of Technology and Spanish Research Council to use Aether 1 Bioprinter for Groundbreaking New 3D Bioprinting Research Projects
2. Myonexus Therapeutics, Inc. Launches to Develop Pioneering, Clinical-Stage Gene Therapies Targeting Limb-Girdle Muscular Dystrophies
3. Former Vice President of Development Operations at XenoPort, Sami Karaborni, PhD, joins NDA Partners as Expert Consultant
4. Catalent Biologics Announces Collaboration with Therachon, Switzerland, to Advance Clinical Development of Innovative Protein Therapy for Achondroplasia
5. Rachel Cervantes Joins University City Science Center as VP Corporate Development
6. Cirrascale Cloud Services Expands Deep Learning Development Offerings with Support for NVIDIA Quadro GP100
7. Industry leaders join Renova Therapeutics to lead preclinical programs into clinical development
8. EyeCRO and MPI Research Partner to Develop New Preclinical Models of Ophthalmic Disease
9. Covalent Metrology Accelerates Development of Advanced Materials with Better, Faster, Cheaper Data
10. Global E. Coli Testing Market to Reach US$2.36 Billion by 2025: Initiatives Aimed at Spreading Awareness Among Developing Nations to Boost Growth, Says TMR
11. Histogen and Worcester Polytechnic Institute Receive Phase II NSF Award to Develop Unique Wound Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... New York, NY (PRWEB) , ... August 15, 2017 , ... ... for the first time on Immuno-Oncology 360° (IO360°) programming through a series of upcoming ... to be held February 7-9, 2018, at The Roosevelt Hotel in New York City. ...
(Date:8/14/2017)... ... August 14, 2017 , ... ... antibodies. Key researchers in the antibody community have recently come together to address ... antibodies in the laboratory. , The team at Thermo Fisher ...
(Date:8/11/2017)... , Aug. 11, 2017  Market ... New York Times article regarding the telemedicine ... according to Kalorama Information.  The article, ... for That"  used information from Kalorama ... Monitoring & Telemedicine Market  (Sleep, Diabetes, ...
(Date:8/11/2017)... ... August 11, 2017 , ... “There is an ... natural alternatives to synthetic ingredients,” said Matt Hundt, President of Third Wave Bioactives. ... manufacturing presence and know-how of Biorigin will allow us to bring truly novel ...
Breaking Biology Technology:
(Date:4/11/2017)... Florida , April 11, 2017 ... a security technology company, announces the appointment of independent Directors ... Bendheim to its Board of Directors, furthering the company,s ... ... of NXT-ID, we look forward to their guidance and benefiting ...
(Date:4/5/2017)... 2017  The Allen Institute for Cell Science today ... one-of-a-kind portal and dynamic digital window into the human ... first application of deep learning to create predictive models ... and a growing suite of powerful tools. The Allen ... future publicly available resources created and shared by the ...
(Date:4/5/2017)... April 4, 2017 KEY FINDINGS ... expand at a CAGR of 25.76% during the forecast ... the primary factor for the growth of the stem ... https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global stem cell ... application, and geography. The stem cell market of the ...
Breaking Biology News(10 mins):